Titlebook: Dyslipidemias in Kidney Disease; Adrian Covic,Mehmet Kanbay,Edgar V. Lerma Book 2014 Springer Science+Business Media New York 2014 Dialysi

Extraneous

書目名稱Dyslipidemias in Kidney Disease影響因子(影響力)




書目名稱Dyslipidemias in Kidney Disease影響因子(影響力)學科排名




書目名稱Dyslipidemias in Kidney Disease網(wǎng)絡(luò)公開度




書目名稱Dyslipidemias in Kidney Disease網(wǎng)絡(luò)公開度學科排名




書目名稱Dyslipidemias in Kidney Disease被引頻次




書目名稱Dyslipidemias in Kidney Disease被引頻次學科排名




書目名稱Dyslipidemias in Kidney Disease年度引用




書目名稱Dyslipidemias in Kidney Disease年度引用學科排名




書目名稱Dyslipidemias in Kidney Disease讀者反饋




書目名稱Dyslipidemias in Kidney Disease讀者反饋學科排名

Minutes

急急忙忙

d by leaders in the field.Includes supplementary material: .Dyslipidemia in chronic kidney disease is a common clinical problem and growing in prevalence. With the recent publication of clinical practice guidelines on the management of lipid related disorders in patients affected by chronic kidney d

refine

接觸

Book 2014lines on the management of lipid related disorders in patients affected by chronic kidney disease, an up-to-date and comprehensive resource of evidence-based literature is needed. .Dyslipidemias in Kidney Disease .captures the growing body of information on this subject matter. This book presents th

斜坡

degradation, and clearance. This chapter examines the lipid profile, underlying pathophysiological mechanism, and treatment of the dyslipidemia observed in patients with nephrotic syndrome, CKD, and diabetic nephropathy.

斜坡

https://doi.org/10.1007/978-1-4614-3903-5ts among elderly patients with kidney dysfunction seem to have a benefit, but the data remain limited. Moreover, it should always be considered that elderly patients with chronic kidney disease are at greater risk of adverse drug reactions; therefore, the lowest possible dose of medications should be used.

女歌星

北極人

arrhythmic

Lipid Nephrotoxicity: New Concept for an Old Disease,distribution and renal vascular injury, and also causes statin resistance. This concept alters traditional understanding of the pathogenesis of lipid-mediated renal and vascular injury, and evaluation of renal and cardiovascular risk and lipid-lowering treatment in such patients.